Rewards for sticking with long-acting injections
Part of Mental health clinical trials.
This study tests whether offering small rewards (like gift cards) can help people stick with a long-acting injection of their medication. It's for people with serious mental health conditions who have had a recent hospital stay or are at high risk of one.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 64 years old.
- You have a diagnosis of schizophrenia, schizoaffective disorder, or bipolar disorder.
- You were involuntarily hospitalized in the past year or are at high risk of being hospitalized.
- Your medication is available as a long-acting shot (given every few weeks or months).
- You live in Allegheny County, Pennsylvania.
- You receive care at a clinic that is part of the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new long-acting injectable medication (S-892216 LAI) in healthy adults. It helps researchers understand how the drug works in the body when given as a shot, which could lead to a treatment given less often in the future.
This study tests a program that uses rewards (contingency management) to help people with opioid use disorder stay in treatment and avoid drug use while they are in the hospital.
This trial tests a personalized exercise program for people with psychosis who take long-acting injectable antipsychotics. The goal is to see if regular physical activity can improve overall health and well-being.
This trial tests a long-acting injectable form of cariprazine (AX251 LAI) for people with stable schizophrenia. You would receive one injection and stay at the clinic for 7 days to see how your body handles it and how well you tolerate it.
This trial tests whether a new version of an extended-release injection is as effective as the original in people with schizophrenia. The study helps ensure patients have access to a reliable treatment option.
This study looks at long-acting (extended-release) antipsychotic medicine options in people with schizophrenia, compared with regular tablets. You may be able to join if you were already part of a related earlier study or its real-world follow-up.
Hear when a new Schizoaffective Disorder trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.